Literature DB >> 33481672

Prior Oral Contraceptive Use and Longer Term Mortality Outcomes in Women with Suspected Ischemic Heart Disease.

Lili Barsky1, Chrisandra Shufelt1, Marie Lauzon1, B Delia Johnson2, Sarah L Berga3, Glenn Braunstein1, Vera Bittner4, Leslee Shaw5, Steven Reis2, Eileen Handberg6, Carl J Pepine6, C Noel Bairey Merz1.   

Abstract

Background: Previous Women's Ischemia Syndrome Evaluation (WISE) work demonstrated prior oral contraceptive (OC) use was associated with lower coronary artery disease (CAD) in women with suspected ischemia. The association of prior OC use with longer term all-cause and cardiovascular disease (CVD) mortality is unclear. Materials and
Methods: WISE women undergoing coronary angiography for suspected ischemia (enrolled 1996-2001) with prior OC use history and 10-year follow-up data were analyzed. A blinded core laboratory assessed atherosclerotic CAD severity. Kaplan-Meier analyses evaluated prior OC use relative to all-cause and CVD mortality. Cox regression analyses adjusted for baseline differences. Mediation, interaction, and multicollinearity were analyzed.
Results: Our 686 women had a mean age 62.5 ± 9.6 years, multiple cardiac risk factors, and 39% previously used OC. Prior OC users were younger, with less lipid-lowering medication use and lower atherosclerotic CAD severity scores (all p < 0.05). Prior OC use was associated with lower 10-year all-cause (p = 0.007) and CVD mortality (p = 0.019). After adjustment, this was no longer significant (p = 0.77 and p = 0.90, respectively). Atherosclerotic CAD severity score mediated one-third of the observed association. Prior OC use was associated with increased CVD mortality among women with very elevated menopausal systolic blood pressure (SBP). Conclusions: Unadjusted prior OC use was associated with lower longer-term all-cause and CVD mortality. One-third of this observed effect appears mediated by the atherosclerotic CAD severity score. Prior OC was adversely associated with CVD mortality in women with very elevated menopausal SBP. Additional investigation is needed to understand the potential benefits and harms of prior OC use. Clinical Trial Number: NCT00000554, or https://www.clinicaltrials.gov/ct2/show/NCT00000554.

Entities:  

Keywords:  WISE; mortality; nonobstructive coronary artery disease; oral contraceptive

Mesh:

Substances:

Year:  2021        PMID: 33481672      PMCID: PMC8098756          DOI: 10.1089/jwh.2020.8743

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   3.017


  25 in total

1.  Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study.

Authors:  S E Reis; R Holubkov; A J Conrad Smith; S F Kelsey; B L Sharaf; N Reichek; W J Rogers; C N Merz; G Sopko; C J Pepine
Journal:  Am Heart J       Date:  2001-05       Impact factor: 4.749

2.  Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis.

Authors:  Jean-Patrice Baillargeon; Donna K McClish; Paulina A Essah; John E Nestler
Journal:  J Clin Endocrinol Metab       Date:  2005-04-06       Impact factor: 5.958

3.  Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies.

Authors:  Angela Boldo; William B White
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

4.  ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives.

Authors: 
Journal:  Obstet Gynecol       Date:  2010-01       Impact factor: 7.661

Review 5.  The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset?

Authors:  Shari S Bassuk; JoAnn E Manson
Journal:  Metabolism       Date:  2016-01-12       Impact factor: 8.694

6.  Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation.

Authors:  C Noel Bairey Merz; B Delia Johnson; Sarah Berga; Glenn Braunstein; Steven E Reis; Vera Bittner
Journal:  Fertil Steril       Date:  2006-04-05       Impact factor: 7.329

7.  Total estrogen time and obstructive coronary disease in women: insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE).

Authors:  C Noel Bairey Merz; B Delia Johnson; Sarah L Berga; Glenn D Braunstein; Ricardo Azziz; Yuching Yang; Steven E Reis; Vera Bittner; T Keta Hodgson; Carl J Pepine; Barry L Sharaf; George Sopko; Sheryl F Kelsey
Journal:  J Womens Health (Larchmt)       Date:  2009-09       Impact factor: 2.681

8.  Serum heat shock protein 27 levels represent a potential therapeutic target for atherosclerosis: observations from a human cohort and treatment of female mice.

Authors:  Tara A Seibert; Benjamin Hibbert; Yong-Xiang Chen; Katey Rayner; Trevor Simard; Tieqiang Hu; Charles M Cuerrier; Xiaoling Zhao; Jacqueline de Belleroche; Benjamin J W Chow; Steven Hawken; Kumanan R Wilson; Edward R O'Brien
Journal:  J Am Coll Cardiol       Date:  2013-06-10       Impact factor: 24.094

9.  Estrogen increases expression of the human prostacyclin receptor within the vasculature through an ERalpha-dependent mechanism.

Authors:  Elizebeth C Turner; B Therese Kinsella
Journal:  J Mol Biol       Date:  2010-01-11       Impact factor: 5.469

10.  The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?

Authors:  Virginia M Miller; Fredrick Naftolin; Sanjay Asthana; Dennis M Black; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; N Maritza Dowling; Carey E Gleason; Howard N Hodis; Muthuvel Jayachandran; Kejal Kantarci; Rogerio A Lobo; JoAnn E Manson; Lubna Pal; Nanette F Santoro; Hugh S Taylor; S Mitchell Harman
Journal:  Menopause       Date:  2019-09       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.